<DOC>
	<DOCNO>NCT02224209</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety stag carotid angioplasty v.s . routine single-stage carotid artery stenting Chinese patient carotid artery stenosis high hyperperfusion risk peri-procedural period .</brief_summary>
	<brief_title>Comparison Staged Angioplasty Routine Single-stage Stenting ( CAS ) Treatment Carotid Artery Stenosis</brief_title>
	<detailed_description>1 . Data Quality Before initiation study site , Cerebrovascular Disease Center Beijing Tiantan Hospital verify whether investigator qualify , inspect study site 's facility , inform investigator responsibility , well correctly completely fill related document . Through investigator training session , investigator team understand trial protocol , CRF trial process , etc . Then start-up visit site initiate . Trial monitor pay start-up visit site , pay first inspection visit soon possible screening/randomization first patient . Afterwards , monitor pay inspection visit regularly trial visit end . They need directly refer source data verify accurate CRF fill conduct inspection/audits . Data enter CRF shall subject examination internal consistency ( within know classification scope ) , external inspection ( data consistent patient 's know data ) trend consistency ( data change exceed allowable range . For example , excess weight loss prompt change dietary status ) . The content trial database include data collect site , abnormal data delay data progress tracking . 2 . File Data Data enter CRF must able verify source data , directly enter CRF . In case , data CRF regard source data , use subsequent data confirmation . Required data patient ' continue treatment shall also routinely record medical record . The site 's investigator shall clearly make patient ' medical record patient participate clinical trial , also require medical staff treatment patient contact trial contact person treatment . To end , investigator shall provide contact information . If patient preserve his/her medical record his/her , study site shall preserve copy trial-related data . Unless related data information directly record CRF , research data must record patient ' medical record ( research document ) , enter CRF early possible . Source data verify primary document use purpose must preserve . Patients ' research document source data shall preserve notice destruction receive sponsor . 3 . Statistical Method Sample Size 3.1 Statistical Analysis This study power primary endpoint hyperperfusion syndrome ( HPS ) rate 30 day post CAS procedure . Superiority analysis perform use two-sample t-test two-sided 5 % alpha level . All secondary endpoint descriptively compare two treatment arm . All analysis perform Per-Protocol ( PP ) population . The PP population consist patient receive treatment per randomization without major protocol deviation . X2 test adopt statistical analysis two group result , supplement compliance protocol actual treatment analysis . The following confounding factor consider analysis determine effect different preset confounding factor prognosis : - Age ; - Sex ; - Blood pressure ; - Degree , location , diameter length lesion stenosis ; - Cerebrovascular collateral compensatory condition ; - Cerebral hemodynamics culprit side ; - Cerebrovascular reserve cerebrovascular autoregulation status culprit side ; - Diameter pressure balloon stage-1 balloon angioplasty ; - Carotid angioplasty experience operate site doctor . Appropriate method employ summarize analyze patient ' baseline characteristic , safety indicator trial ( include treatment interruption/termination , lifestyle assessment , concomitant medication , etc. ) . Multi-variant method employ analyze effect demographic factor primary result . All detail statistical analysis show separate 'Statistical Analysis Plan ' ( SAP ) . 3.2 Sample Size The sample size calculation primary endpoint HPS rate 30 day post CAS procedure base follow assumption : Two-tailed superiority test = 0.05 Power = 90 % Randomization ratio 1 ( stag angioplasty arm ) : 1 ( routine single-stage CAS arm ) The rate HPS rate expect 0.16 per subject procedure regular CAS arm high hyperperfusion risk patient base previous study . The rate HPS rate presume 0.02 per subject procedure stag CAS arm high hyperperfusion risk patient depend study Yoshimura , Kyung Mi Lee u . A total 150 subject estimate required . Given assumption , sample size 150 ( 75 Staged CAS : 75 regular CAS ) require . To account estimated 5 % dropout rate , approximately 158 patient enrol . Of 158 patient , 79 randomize Staged CAS arm 79 randomize regular CAS arm . The sample size calculation perform use SAS software , version 9.3 ( SAS Institute ) . 4 . Collection data procedure - Nerve function evaluation - NIHSS - mRS - Blood pressure - TCD - Laboratory examination - CT , MR</detailed_description>
	<mesh_term>Constriction , Pathologic</mesh_term>
	<mesh_term>Carotid Stenosis</mesh_term>
	<criteria>Patient must 40~80 year age Patient symptomatic carotid stenosis ( defined stroke/TIA patient within 90 day he/she take least one antithrombotic drug intervention vascular risk factor like hypertension hyperlipidemia ) DSA show percent carotid stenosis≥90 % ( quantification stenosis accord NASCET method ) ; near occlusion Angiogram show insufficient collateral circulation culprit vessel surround area : 1 . Cerebral CT perfusion imaging show hypoperfusion culprit vessel surround area , 2 . DSA show collateral circulation assessment &lt; 2 , 3 . MRI cerebral imaging show hemodynamic ischemic lesion CT perfusion imaging show cerebral blood flow culprit side 20 % low lateral brain Lesion length narrow part &lt; 25mm Note : Grading angiographic collateral circulation Grade 0 : No collateral circulation area dominate culprit vessel Grade 1 : Slow collateral circulation surround area , fill defect exist Grade 2 : Fast collateral circulation , area still fill defect Grade 3 : Collateral circulation slow , complete fill see vein late stage Grade 4 : Complete fast collateral circulation , without fill defect Diffusive stenosis cerebral artery MRI cerebral imaging show perforate artery occlusion Cerebral hemorrhage culprit vessel surround area within 6 week ; potential thrombus heart Subsequent cerebral tumor , cerebral aneurysm , arteriovenous abnormality Known contraindication heparin , aspirin , ticlopidine , aesthetic , contrast ; blood hemoglobin &lt; 10g/dl , blood platelet &lt; 100000 Severe nerve dysfunction culprit vessel surround area cerebral infarction ( mRS≥3 ) INR &gt; 1.5 ( irreversible ) , uncorrectable bleeding risk factor , life expectancy &lt; 1 year Women pregnant breast feed Committee adjudicate inclusion criterion find patient unsuitable stag angioplasty carotid artery stenosis Unsuccessful placement proximal distal EPD procedure The target vessel angle≧45 Participate clinical trial within three month</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>Carotid artery stenosis</keyword>
	<keyword>High risk hyperperfusion</keyword>
	<keyword>Staged angioplasty</keyword>
	<keyword>Routine single-stage stenting</keyword>
</DOC>